Stephens set a $45.00 price target on Myriad Genetics (NASDAQ:MYGN) in a report issued on Wednesday. The firm currently has a buy rating on the stock.

“We initiate coverage of Nightstar Therapeutics (NITE) with a Buy rating (PT$40), on the market opportunity likely addressed by NSR- REP1 in choroideremia (CHM). Choroideremia is a rare, inherited degenerative disease of the retina that typically has onsets in childhood or early adolescence. Patients then progress to reach legal or complete blindness in their 40s or 50s. There are currently no FDA-approved disease-modifying therapies for CHM. Nightstar’s lead asset, AAV-based gene therapy, NSR-REP1, is due to enter the 140-patient pivotal phase III STAR trial in 1H18 for the treatment of CHM. With the Lancet-published phase I/II data for NSR-REP1 in CHM, and subsequent updates from the multi-center program, Nightstar has been able to show that all NSR-REP1- treated patients who received the therapeutic dose were able to maintain vision to 5 years after treatment.”,” Stephens’ analyst commented.

Other analysts also recently issued research reports about the stock. ValuEngine raised shares of Myriad Genetics from a hold rating to a buy rating in a research note on Friday, November 10th. Zacks Investment Research downgraded shares of Myriad Genetics from a strong-buy rating to a hold rating in a research note on Friday, December 15th. Deutsche Bank lifted their price target on shares of Myriad Genetics from $28.00 to $30.00 and gave the company a hold rating in a research note on Wednesday, November 8th. Cowen reaffirmed a hold rating and set a $25.00 price target on shares of Myriad Genetics in a research note on Sunday, September 17th. Finally, Leerink Swann reaffirmed a market perform rating and set a $31.00 price target on shares of Myriad Genetics in a research note on Monday, October 2nd. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and three have assigned a buy rating to the company’s stock. The company currently has a consensus rating of Hold and a consensus price target of $29.73.

Myriad Genetics (NASDAQ:MYGN) opened at $34.83 on Wednesday. The company has a market capitalization of $2,380.50, a PE ratio of 23.38, a P/E/G ratio of 2.18 and a beta of 0.24. Myriad Genetics has a 12-month low of $15.15 and a 12-month high of $37.30. The company has a debt-to-equity ratio of 0.09, a current ratio of 2.34 and a quick ratio of 2.06.

Myriad Genetics (NASDAQ:MYGN) last released its quarterly earnings results on Tuesday, November 7th. The company reported $0.26 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.21 by $0.05. The company had revenue of $190.20 million during the quarter, compared to analyst estimates of $183.52 million. Myriad Genetics had a return on equity of 9.54% and a net margin of 13.28%. The firm’s revenue was up 7.2% on a year-over-year basis. During the same quarter last year, the business posted $0.23 earnings per share. analysts expect that Myriad Genetics will post 1.05 EPS for the current year.

In other news, insider Alexander Ford sold 3,031 shares of the business’s stock in a transaction on Monday, November 13th. The shares were sold at an average price of $31.64, for a total transaction of $95,900.84. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Walter Phd Gilbert sold 7,500 shares of the business’s stock in a transaction on Thursday, December 14th. The shares were sold at an average price of $33.19, for a total transaction of $248,925.00. The disclosure for this sale can be found here. Insiders sold 16,531 shares of company stock worth $545,826 over the last ninety days. Corporate insiders own 6.70% of the company’s stock.

Several institutional investors and hedge funds have recently made changes to their positions in the company. CS Mckee LP lifted its position in Myriad Genetics by 0.3% during the second quarter. CS Mckee LP now owns 30,000 shares of the company’s stock valued at $775,000 after purchasing an additional 100 shares during the period. Public Employees Retirement System of Ohio lifted its position in Myriad Genetics by 1.0% during the second quarter. Public Employees Retirement System of Ohio now owns 143,036 shares of the company’s stock valued at $3,696,000 after purchasing an additional 1,480 shares during the period. TrimTabs Asset Management LLC lifted its position in Myriad Genetics by 17.2% during the third quarter. TrimTabs Asset Management LLC now owns 11,798 shares of the company’s stock valued at $427,000 after purchasing an additional 1,728 shares during the period. Riverhead Capital Management LLC lifted its position in Myriad Genetics by 80.9% during the second quarter. Riverhead Capital Management LLC now owns 4,161 shares of the company’s stock valued at $107,000 after purchasing an additional 1,861 shares during the period. Finally, Stifel Financial Corp lifted its position in Myriad Genetics by 3.6% during the third quarter. Stifel Financial Corp now owns 54,408 shares of the company’s stock valued at $1,968,000 after purchasing an additional 1,900 shares during the period.

COPYRIGHT VIOLATION NOTICE: This piece was first reported by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another domain, it was stolen and reposted in violation of United States and international copyright and trademark law. The original version of this piece can be viewed at https://www.watchlistnews.com/stephens-analysts-give-myriad-genetics-mygn-a-45-00-price-target/1797394.html.

Myriad Genetics Company Profile

Myriad Genetics, Inc is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence.

Analyst Recommendations for Myriad Genetics (NASDAQ:MYGN)

Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with Analyst Ratings Network's FREE daily email newsletter.